Pharmacokinetics
Introduction to Population PK

Helmut Schütz
BEBAC

PopPK: History

- 1972 The Birth of Population PK (FO)

COMPUTERS AND BIOMEDICAL RESEARCH 5, 441-459 (1972)

Modelling of Individual Pharmacokinetics for Computer-Aided Drug Dosage*

LEWIS B. SHEINER, BARR ROSENBERG, AND KENNETH L. MELMON

*Departments of Medicine and Pharmacology, Division of Clinical Pharmacology,
University of California San Francisco Medical Center, San Francisco, California 94122*

Received August 12, 1971

PopPK: History

- 1977 NONMEM group established at UCSF (L. Sheiner, S. Beal)

- 1979 First NONMEM FO program

- 1986 First nonparametric method: NPML (A. Mallet)

- 1990 First FOCE method (M. Lindstrom, D. Bates)

- 1990 First Bayesian method: BUGS and PKBugs (A. Gelfand, A. Smith)

intra individual variability

inter individual variability

residual error

Classical PK modeling
(individual fits)

Population PK modeling
(individual fits + mean PK)

Classical PK *vs.* PopPK

- Classical PK
  - Two-Stage Approach
    1. Fitting individuals
    2. Averaging individuals' PK parameters; calculate variances
    - *Which* average?
      Geometric mean (V, CL), harmonic mean (k), median (t_{lag}), …
    - What if individuals best fitted by different models?
    - Covariates by regression analysis

Classical PK *vs.* PopPK

- Population PK
  - Simultaneous fit of all data
    - Separation of residual error into intra- and inter-individual components
    - Direct assessment of covariates

Classical PK *vs.* PopPK

- Example
  - One compartment, lag-time, n=6

		V (SD)	%RE	k_a (SD)	%RE	k_{el} (SD)	%RE	t_{lag}	%RE
theoretical		0.5000		1.3900		0.1738		1.0000	
classical	1	0.3416		1.2254		0.2153		0.8156	
	2	0.4982		1.4340		0.1640		0.8361	
	3	0.3596		1.2432		0.2070		0.8330	
	4	0.3231		0.9238		0.1856		0.8066	
	5	0.4077		1.2692		0.1636		0.8392	
	6	0.5786		1.6706		0.1519		0.8606	
	average	0.4087 0.0951	−18.3	1.2741 0.2628	−8.3	0.1797 0.0247	+3.4	0.8346	−16.5
naïve pooled		0.4951 0.1152	−1.0	1.9743 2.4785	+42.0	0.0963 0.0711	−44.6	0.7549 0.5184	−24.5
FOCE LB		0.4067	−18.7	1.2395	−10.8	0.1814	+4.4	0.8283	−17.2

Basics

- Nonlinear Mixed Effects Model
- Estimates Population PK parameters (V, CL, …): Fixed effects (thetas θ)
- Estimates variability
  - Random effects (etas η)
    - Intersubject variability
    - Interoccasion variability (day to day)
  - Residual error (epsilons ε)
   - Intrasubject: measurement error, model misspecification, …

Basics

- Identify factors determining intersubject variability: Covariates
  - Demographics: Age, body weight / surface area, sex, …
  - Genotypes: CYP450, …
  - Physiology: Renal (creatinine clearance) or hepatic impairment, disease state, …
  - Concomitant drugs
  - Others: Food, circadian variation, formulation, …

Model

$y_{ij} = f(\Theta_i) + \varepsilon_{ij}$, where

- y_{ij} is the jth observation of the ith subject
- f is a model that describes all observations
- Θ_i is a vector of subject i's parameter values (θ)
- ε_{ij} is the residual error of subject i's j[th] observation

- The elements of Θ_i are usually $\theta_i = \theta * e^{\eta}$, where
  - θ is the typical value for a parameter
  - ε^2 is the variance of η values

Pyry Välitalo, University of Kuopio, 1.10.2009

Components

Fixed effects

Structural model
How many compartments, how to model elimination?

Random effects

Covariate model
E.g., weight effect on clearance and volume of distribution

Statistical model
How to model inter-subject, between-occasion residual vari-ability?

Pyry Välitalo, University of Kuopio, 1.10.2009

Advantages

- Studies in the target population
- Sparse sampling (2–3 samples / subject)
  - Routine sampling in Phase II/III
  - Special populations (Pediatrics, cancer/AIDS, critical care patients, eldery, …)
- Missing data in 'rich data sets' not problematic
  - Imbalanced designs common
    - Different number of samples / subject
    - Different sampling times / subject

Advantages

- Covariates part of the model
  - Fewer restrictions on in-/exclusion criteria
  - 'What if' scenarios in planing further studies
  - Full model allows prediction of 'real world PK': more reliable dose regimen / posology

Disadvantages

- Complex methodology
  - Might require simulations (optimal sampling times); stepwise refinement of model during study
  - Statistical models not trivial
  - Expensive software with steep learning curve
  - Carl Metzler: *"PK Modeling – Art or Science?"*
- Time consuming
  - Easily ~10times longer than classical Two-Stage PK even by an experienced modeler

Disadvantages

- Validation might require multiple studies
  - Internal validation:
    Use only part of the data to set up a model and compare predictions with other part
  - External validation:
    Predictions *vs.* another study

- Cost/Benefit ratio
  - Unclear beforehand whether the model will give more than a trivial result (like: concentrations depend on body weight)

Example

- Intravenous dose, parameterized in CL and V, covariates: sex (categ.), weight, age (cont.) first 12 of 100 subjects (internal validation)

  - $A_{t=0}$ = Dose
    dA/dt = $-A \cdot CL/V$
    IPRED = A/V
    Y = IPRED + ε

  - Base model
    - Five parameters
      V = $\theta V * e^{\eta(V)}$
      CL = $\theta CL * e^{\eta(CL)}$
      Residual error (σ)

Example

Example

- Covariate model 1 (+ weight on V/CL, + age on CL)
 - Eight parameters
    $V = \theta V*(w/75)*e^{\eta(V)}$ scaling (cent. at 75 kg)
    $CL = \theta CL*(w/75)*(a/40)*e^{\eta(CL)}$ scaling (cent. at 75 kg / 40 a)
    Residual error (σ)

Example

Example

- Covariate model 2 (like 1 + sex on CL); categorial coding: male = 0, female = 1
  - Nine parameters
    $V = \theta V*(w/75)*((sex == 1)*\theta s1)*e^{\eta(V)}$ affects only females
 $CL = \theta CL*(w/75)*(a/40)*e^{\eta(CL)}$
    Residual error (σ)

Example

| model	θ	Estimate	CV%	AIC
base	V	10.582	11.600	−376.29
	CL	0.14682	7.7574	
	σ	0.086799	11.207	
covariate 1	V	9.2987	9.9556	−373.23
	CL	0.13512	8.5915	
	σ	0.086927	11.790	
	Vw	1.1300	56.603	
	VCL	0.92790	37.907	
	CLa	0.25116	77.422	
covariate 2	V	10.220	16.731	−366.07
	CL	0.11729	10.174	
	σ	0.084502	12.187	
	Vw	1.0697	66.305	
	VCL	1.4051	28.701	
	CLa	0.49579	40.647	
	Vsex	−0.048653	413.77	

Yes, but which model?

Example

base model • cov. 1 model • cov. 2 model

Example

cov. 2 model (males)

cov. 2 model (females)

Example

cov. 2 model
(males)

cov. 2 model
(females)

Legend:
— 05%, 05%
— 05%, 50%
— 05%, 95%
— 50%, 05%
— 50%, 50%
— 50%, 95%
— 95%, 05%
— 95%, 50%
— 95%, 95%
• observed

Predictive check / internal validation
Model based on first 12 subjects and observations of other 88 subjects
Estimated intersubject variabilities η too small; biased θ?
Better to estimate the model from 50% of subjects.

Example

cov. 2 model
(males)

cov. 2 model
(females)

Legend:
- 05%, 05%
- 05%, 50%
- 05%, 95%
- 50%, 05%
- 50%, 50%
- 50%, 95%
- 95%, 05%
- 95%, 50%
- 95%, 95%
- observed

Predictive check / internal validation

Model based on first 50 subjects and observations of other 50 subjects

Model seems to be suitable for females only. Consider to go back to covariate 1 model (without stratification for sex).

Software

- NONMEM 7.3 (iconplc ~5500 U$/a)
- Phoenix/NLME 1.3 (Pharsight ~1900 U$/a)
- Monolix 4.2 (Lixosoft ?U$)
- SimBiology for MATLAB (Mathworks 3000 €)
- PopKinetics for SΛΛM II (TEG ?U$)
- Kinetica 5.0 (Thermo ~900 U$/a)
- Shareware
  - Pmetrics for R (USC/LAPK 895 U$ suggested)
    http://www.lapk.org/pmetrics.php

Software

- Freeware
  - ADAPT 5 (USC/BMSR)
    http://bmsr.usc.edu/software/adapt/
  - Boomer (David Bourne)
    http://www.boomer.org/
  - SAEMIX 0.96.1 for R
    http://cran.r-project.org/web/packages/saemix/index.html
  - PKTools/WinBUGS/PKBUGS (SD only)
    http://cran.r-project.org/web/packages/PKtools/index.html
    http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml
    http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/pkbugs.shtml

Still an Art?

- One compartment, 1st order absorption
  - 100 simulated datasets
  - 100 individuals / dataset
  - 4 samples / individual
  - Missing points at random (25%)
  - Initial estimates suggested for fixed effects
  - Blinded analysis by very experienced modelers
  - Software: SAS Prox nlmixed (FO and adaptive Gaussian), NONMEM V / VI FOCE, S-Plus nlme, ITPS, PEM, PEM, MCPEM, SAEM (Monolix)

Girard & Mentré, PAGE, Pamplona 2005

Still an Art?

V true= 27.2

Ke true= 0.232

Ka-Ke true= 0.304

Thank You!
Introduction to Population PK
Open Questions?

Helmut Schütz
BEBAC
Consultancy Services for
Bioequivalence and Bioavailability Studies
1070 Vienna, Austria
helmut.schuetz@bebac.at

References

- Sheiner LB, Rosenberg B, and KL Melmon
  Modelling of individual pharmacokinetics for computer-aided drug dosage
 Comput Biomed Res 5/5, 441-59 (1972)
- Sheiner LB and SL Beal
  NONMEM Users Guide
  San Francisco: Division of Pharmacology: University of California (1979)
- Sheiner LB and SL Beal
  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data
  J Pharmacokin Biopharm 8/6, 553–71 (1980)
- Sheiner LB and SL Beal
  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data
  J Pharmacokin Biopharm 9/5, 635–51 (1981)
- Sheiner LB and SL Beal
  Some suggestions for measuring predictive performance
  J Pharmacokinet Biopharm 9/4, 503–12 (1981)
- Beal SL and LB Sheiner
  Estimating population kinetics
  Crit Rev Biomed Eng 8/3, 195–222 (1982)
- Sheiner LB and SL Beal
  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data
  J Pharmacokin Biopharm 11/3, 303–19 (1983)
- A Mallet
  A maximum likelihood estimation method for random coefficient regression models
  Biometrika 3, 645–56 (1986)
- Sheiner LB and SL Beal
  A note on confidence intervals with extended least squares parameter estimation
  J Pharmacokin Biopharm 15/1, 93–8 (1987)
- Mallet A, Mentré F, Gilles J, Kelman AW, Thomson AH, Bryson SM, and B Whiting
  Handling covariates in population pharmacokinetics, with an application to gentamicin
  Biomed Meas Infor Contr 3, 138–46 (1988)
- Lindstrom M and D Bates
  Nonlinear Mixed Effects Models for Repeated Measures Data
  Biometrics 46/3, 673–87 (1990)
- Gelfand AE and AFM Smith
  Sampling-based approaches to calculating marginal densities
  J Am Stat Assoc 85, 721–41 (1990)

References

- Thomas A, Spiegelhalter DJ, and WR Gilks
  BUGS: a program to perform Bayesian inference using Gibbs sampling. In: *Bayesian Statistics*, Bernardo JM, Berger JO, Dawid AP, and AFM Smith AFM (eds), vol. 4
  Oxford University Press: Oxford, UK, 837–42 (1992)
- Mentré F and R Gomeni R
  A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics
  J Biopharm Stat 5, 141–58 (1995)
- Pinheiro J and D Bates
  Mixed-Effects Models in S and S-PLUS
  Springer Verlag: New York, USA (2000)
  ISBN 978-1-4419-0317-4
- Beal SL, Sheiner LB, and AJ Boeckmann AJ
  NONMEM users guides (1989–2006)
  icon development solutions: Ellicott City, MD, USA
- Zhang L, Beal SL, and LB Sheiner LB
  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance
  J Pharmacokinet Pharmacodyn 30/6, 387–404 (2003)

- Zhang L, Beal SL, and LB Sheiner LB
  Simultaneous vs. sequential analysis for population PK/PD data I: robustness of methods
  J Pharmacokinet Pharmacodyn 30/6, 405–416 (2003)
- Kuhn E and M Lavielle M
  Maximum likelihood estimation in nonlinear mixed effects models
  Comput Stat Data Anal 49, 1020–38 (2005)
- Girard P and F Mentré
  A comparison of estimation methods in nonlinear mixed effects models using a blind analysis
  PAGE Meeting: Pamplona, Spain (16–17 June 2005)
  http://www.page-meeting.org/page/page2005/PAGE2005O08.pdf
- DJ Lunn
  Bayesian analysis of population pharmacokinetic / pharmaco-dynamic models. In: *Probabilistic Modeling in Bioinformatics and Medical Informatics*, Husmeier D, Dybowski R and S Roberts S (eds). Springer: London, UK, 351–70 (2005)
- Bauer RJ, Guzy S and C Ng
  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples
  AAPS J 9/1, E60–83 (2007)

References

- Lunn D *et al.*
  Combining MCMC with 'sequential' PKPD modelling
  J Pharmacokinet Pharmacodyn 36/1, 19–38 (2009)
  DOI: 10.1007/s10928-008-9109-1
- Lunn D *et al.*
  The BUGS project: Evolution, critique and future directions
  Statist Med 28/25, 3049–3188 (2009)
  DOI: 10.1002/sim.3680
- Pandhard X and A Samson
  Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects
  Biostatistics 10/1, 121–35 (2009)
- P Bonate
  Pharmacokinetic-Pharmacodynamic Modeling and Simulation
  Springer Verlag: New York, USA (2nd ed. 2011)
  ISBN 978-1-4419-9484-4
- Neely MN *et al.*
  Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmaco-metric Modeling and Simulation Package for R
  Therapeutic Drug Monitoring 34/4, 467–76 (2012)

- Chan PLS *et al.*
  The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects
  J Pharmacokinet Pharmacodyn 38, 41–61 (2011)
  DOI: 10.1007/s10928-010-9175-z
- FDA/CDER/CBER
  - *Guidance for Industry. Population Pharmacokinetics* (February 1999)
    http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf
- EMA/CHMP
  - *Guideline on the Role of Pharmacokinetics in the Deve-lopment of Medicinal Products in the Paediatric Popu-lation*
    EMEA/CHMP/EWP/147013/2004 (June 2006)
    http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003066.pdf
  - *Guideline on Reporting the Results of Population Phar-macokinetic Analyses*
    CHMP/EWP/185990/06 (June 2007)
    http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003067.pdf